Carasent

Prospectus • Nov 29, 2024

Carasent AB (publ) publishes prospectus in connection with its listing on Nasdaq Stockholm

Carasent AB (publ) publishes prospectus in connection with its listing on Nasdaq Stockholm

Carasent AB (publ) ("Carasent" or the "Company") today publishes a prospectus

in connection with the Company's listing of its shares on Nasdaq Stockholm.

GOTHENBURG, 29 November 2024

On 30 August 2024, it was announced that the Company had adopted a

cross-border merger plan with Carasent ASA, with the Company as the acquiring

entity, in order to effect the relisting of Carasent ASA's shares on Nasdaq

Stockholm (the "Relisting"). On 8 November 2024, it was announced that Nasdaq

Stockholm had assessed that Nasdaq Stockholm's listing requirements have been

fulfilled and that Nasdaq Stockholm will approve an application for admission

to trading of the Company's shares, subject to the fulfilment of certain

customary conditions, including the approval and registration of a prospectus

by the Swedish Financial Supervisory Authority.

The Swedish language prospectus in relation to the Relisting has today been

approved by the Swedish Financial Supervisory Authority and is available on

the Company's website, www.carasent.com (http://www.carasent.com/). The

prospectus will also be available on the Swedish Financial Supervisory

Authority's website, www.fi.se (http://www.fi.se/).

The cross-border merger is expected to be completed on 4 December 2024, upon

which shareholders will have their shares in Carasent ASA exchanged

one-for-one with shares in the Company. The last day of trading on Oslo Børs

is expected to be 4 December 2024 and the first day of trading on Nasdaq

Stockholm is expected to be 9 December 2024. The dates can be changed and if

so, this will be separately announced.

Carnegie Investment Bank AB is acting as sole financial advisor to Carasent,

Advokatfirman Vinge is acting as legal advisor to Carasent on Swedish legal

matters and Advokatfirmaet BAHR are acting as legal advisor to Carasent on

Norwegian legal matters.

For further information, please contact

Daniel Öhman, CEO

Tel: +46 70-855 37 07, e-mail: daniel.ohman@carasent.com

Svein Martin Bjørnstad, CFO

Tel: +47 979 69 493, e-mail: svein.martin.bjornstad@carasent.com

The information was submitted for publication, through the agency of the

contact persons set out above, on 29 November 2024 at 14.20 CET.

Carasent AB (publ) (Nasdaq Stockholm: CARA) delivers cloud based EHR

solutions, with Webdoc as the leading platform, and a broad ecosystem of

platform services, including solutions for patient communication and business

intelligence. Since 2020 six acquisitions have been completed, adding new

products to the portfolio, including the EHR solutions Metodika, Ad Curis and

Ad Opus, the business intelligence software Medrave and occupational care

platform HPI. The ecosystem of solutions makes Carasent a one-stop shop for

clinics and can cover all needs. Carasent believes in innovation that offers a

new kind of accessibility and availability for patients and practices. The

growing product portfolio comprises market-leading software solutions

developed closely with customers and the respective target market.

IMPORTANT INFORMATION

The publication, release or distribution of this press release may be

restricted in certain jurisdictions. Recipients of this press release in the

jurisdictions in which this press release has been published, released or

distributed should inform themselves about and observe such restrictions. This

press release does not constitute an offer, or a solicitation of any offer, to

buy or subscribe for any securities in Carasent in any jurisdiction.

This press release does not identify or attempt to identify any risks (direct

or indirect) that may be associated with an investment in securities of

Carasent. The information contained in this press release is published for

background purposes only and does not purport to be complete.

This press release does not constitute an offer or invitation to purchase or

subscribe for securities in the United States. The securities referred to

herein may not be sold in the United States absent registration or an

applicable exemption from registration under the U.S. Securities Act of 1933,

as amended. The information contained in this press release may not be

announced, published, copied, reproduced or distributed, directly or

indirectly, in whole or in part, in or into the United States, Australia,

Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland,

Singapore, South Africa, South Korea or any other jurisdiction where such

announcement, publication or distribution of this information would be

contrary to applicable laws and regulations.

This press release is not a prospectus as defined in Regulation (EU) 2017/1129

(the "Prospectus Regulation") and has not been approved by any regulatory

authority in any jurisdiction. Carasent has not authorized any offer of

securities to the public in any member state of the European Economic Area

("EEA").

This press release contains certain forward-looking statements that reflect

the Company's current views with respect to future events and financial and

operational performance. Words such as "intends", "expects", "anticipates",

"may", "plans", "believes", "estimates" and other expressions that are

indicative or predictive of future developments or trends, and that are not

based on historical facts, constitute forward-looking statements. By its

nature, forward-looking information involves known and unknown risks and

uncertainties because it is dependent on future events and circumstances.

Forward-looking statements are not guarantees of future performance or

development and actual results may differ materially from those expressed in

the forward-looking statements.